# A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

> **NCT05093907** · PHASE1,PHASE2 · RECRUITING · sponsor: **BeyondBio Inc.** · enrollment: 27 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** BEY1107
- **COMBINATION_PRODUCT:** Capecitabine

## Key facts

- **NCT ID:** NCT05093907
- **Lead sponsor:** BeyondBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-31
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093907, "A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05093907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*